Study finds Pfizer’s antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week
admin Pfizer’s COVID antiviral Paxlovid appears to have little or no benefit for younger adults, although…
Read More